However, if on the one hand we are now able to exclude from anti-EGFR treatment patients with putative refractory colorectal tumours (i.e., those harbouring a K-RAS mutant status), on the other hand we are still incapable to accurately select responding patients among those without K-RAS mutations. This evidence concerns the gene KRAS and colorectal neoplasm.